Endurance Wealth Management Inc. boosted its stake in shares of Allergan PLC. (NYSE:AGN) by 1.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,671 shares of the company’s stock after buying an additional 456 shares during the period. Endurance Wealth Management Inc.’s holdings in Allergan PLC. were worth $6,133,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Appaloosa LP increased its position in Allergan PLC. by 249.8% in the fourth quarter. Appaloosa LP now owns 4,261,406 shares of the company’s stock valued at $894,938,000 after buying an additional 3,043,097 shares during the period. Janus Capital Management LLC increased its position in Allergan PLC. by 20.5% in the fourth quarter. Janus Capital Management LLC now owns 3,897,873 shares of the company’s stock valued at $818,699,000 after buying an additional 663,390 shares during the period. Baupost Group LLC MA increased its position in Allergan PLC. by 71.5% in the fourth quarter. Baupost Group LLC MA now owns 3,432,603 shares of the company’s stock valued at $720,881,000 after buying an additional 1,430,625 shares during the period. Norges Bank bought a new position in Allergan PLC. during the fourth quarter valued at about $682,333,000. Finally, Edgewood Management LLC bought a new position in Allergan PLC. during the fourth quarter valued at about $530,518,000. 84.88% of the stock is owned by institutional investors and hedge funds.
Shares of Allergan PLC. (NYSE:AGN) opened at 235.49 on Friday. The firm has a market cap of $79.09 billion, a PE ratio of 7.34 and a beta of 1.16. The stock’s 50 day moving average is $230.75 and its 200-day moving average is $226.62. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $261.27.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Tuesday, May 9th. The company reported $3.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.32 by $0.03. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The firm had revenue of $3.57 billion for the quarter, compared to analyst estimates of $3.53 billion. During the same quarter in the prior year, the company posted $3.04 earnings per share. Allergan PLC.’s quarterly revenue was up 5.1% on a year-over-year basis. On average, equities analysts predict that Allergan PLC. will post $16.08 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 15th. Investors of record on Thursday, May 18th were issued a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date of this dividend was Tuesday, May 16th. Allergan PLC.’s dividend payout ratio is presently 9.63%.
WARNING: “Endurance Wealth Management Inc. Buys 456 Shares of Allergan PLC. (AGN)” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://transcriptdaily.com/2017/06/17/allergan-plc-agn-position-raised-by-endurance-wealth-management-inc-updated.html.
AGN has been the topic of several recent analyst reports. Piper Jaffray Companies set a $205.00 price objective on shares of Allergan PLC. and gave the company a “hold” rating in a report on Wednesday, February 22nd. Cowen and Company set a $400.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. Vetr upgraded shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $256.33 price objective on the stock in a report on Wednesday, March 1st. Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. Finally, Mizuho cut their price objective on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a report on Friday, June 9th. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $272.13.
In related news, Director Nesli Basgoz sold 1,889 shares of the company’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.36% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.